The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Relmada expects to initiate its Phase 3 program in the first half of 2026
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated